Advances in Interventional Oncology in Hepatocellular Carcinoma Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 25 October 2026 | Viewed by 1362
Editors
Interests: cancer therapy; treatment; arterial and venous embolization; interventional radiology; cancer biomarkers
Special Issues, Collections and Topics in MDPI journals
Interests: cancers
Special Issue Information
Dear Colleagues,
Hepatocellular carcinoma (HCC) is associated with a high incidence and mortality globally despite advances in systemic therapies. Interventional Oncology (IO) therapies have emerged as promising additional treatment options for HCC. Interventional Oncology encompasses a wide spectrum of diagnostic and therapeutic tools for HCC treatment, including imaging modalities and biopsies to diagnose new HCCs, as well as advanced locoregional therapies such as radioembolization, thermal ablation, and intratumoral therapies. In the era of targeted immunotherapy for HCC, IO is becoming an even more crucial component of personalized, precision HCC treatment because it is customizable for each patient and each HCC. Furthermore, IO techniques have become increasingly sophisticated as more scientific and clinical outcome data have become available.
In this Special Issue, “Advances in Interventional Oncology in Hepatocellular Carcinoma Treatment,” we aim to collaborate and share the latest, cutting-edge research, clinical trials, and comprehensive systematic reviews, including meta-analyses of advanced IO therapies in HCC.
Dr. Edward W. Lee
Dr. XiaoLi Zhu
Dr. Frank Hao
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatocellular carcinoma
- interventional oncology
- HCC
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
